If approved, ZAMTO Cell would be the first dual-target CAR-T therapy ... institutions are now working on CAR-T therapies targeting not just B-cell lymphoma but also multiple myeloma and solid ...

In the U.S., hematologic cancers such as leukemia, lymphoma ... for CAR T-cell therapy increased from 2.7% in 2017 to 3.9% in 2023. Additionally, ongoing research focuses on expanding target ...

Researchers in South Korea have proposed a novel cancer immunotherapy approach that could complement existing CAR-T (Chimeric Antigen Receptor T-cell) treatments.

Approval based on Phase III STARGLO study where Columvi in combination with chemotherapy showed a 41% reduction in the risk ...

or CAR T cell therapy, where a patient's immune cells are taken out, grown and modified to specifically target certain cancers such as the aggressive lymphoma Cannella had. When he was first ...

Roche’s bispecific antibody, Columvi receives European approval for diffuse large B-cell lymphoma after initial therapy: Basel Tuesday, April 15, 2025, 10:00 Hrs [IST] Roche ann ...

More specifically, CAR-T cell therapy engineers a patient’s own immune cells (T-cells) to detect, target, and destroy ... refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal ...

Single-cell RNA sequencing (scRNA-seq) has confirmed that MM exhibits high intra-tumor heterogeneity, comprising a mixture of ...

Creating cancer therapies based around natural killer cells could offer similar levels of efficacy to CAR-T therapies ... Rezvani said: “We could target more than one hundred diseases, bringing ...

Gilead Sciences, Inc. ( NASDAQ: GILD) Q1 2025 Earnings Conference Call April 24, 2025 4:30 PM ET Jacquie Ross - SVP, Treasury & IR Daniel O'Day - Chairman, CEO Johanna Mercier - Chief Commercial ...